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Background: The purpose of this study was to demonstrate how magnetic resonance imaging (MRI) patient
position protocols influence registration quality in patients with oropharyngeal cancer undergoing radical
radiotherapy and the consequences for gross tumour volume (GTV) definition and radiotherapy planning.
Methods and materials: Twenty-two oropharyngeal patients underwent a computed tomography (CT), a
diagnostic MRI (MRID) and an MRI in the radiotherapy position within an immobilization mask (MRIRT). Clinicians
delineated the GTV on the CT viewing the MRID separately (GTVC); on the CT registered to MRID (GTVD) and on the
CT registered to MRIRT (GTVRT). Planning target volumes (PTVs) were denoted similarly. Registration quality was
assessed by measuring disparity between structures in the three set-ups. Volumetric modulated arc therapy (VMAT)
radiotherapy planning was performed for PTVC, PTVD and PTVRT. To determine the dose received by the reference
PTVRT, we optimized for PTVC and PTVD while calculating the dose to PTVRT. Statistical significance was determined
using the two-tailed Mann–Whitney or two-tailed paired student t-tests.
Results: A significant improvement in registration accuracy was found between CT and MRIRT versus the MRID
measuring distances from the centre of structures (geometric mean error of 2.2 mm versus 6.6 mm). The mean
GTVC (44.1 cm
3) was significantly larger than GTVD (33.7 cm
3, p value = 0.027) or GTVRT (30.5 cm
3, p value = 0.014).
When optimizing the VMAT plans for PTVC and investigating the mean dose to PTVRT neither the dose to 99%
(58.8%) nor 95% of the PTV (84.7%) were found to meet the required clinical dose constraints of 90% and 95%
respectively. Similarly, when optimizing for PTVD the mean dose to PTVRT did not meet clinical dose constraints for
99% (14.9%) nor 95% of the PTV (66.2%). Only by optimizing for PTVRT were all clinical dose constraints achieved.
Conclusions: When oropharyngeal patients MRI scans are performed in the radiotherapy position there are
significant improvements in CT-MR image registration, target definition and PTV dose coverage.
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With intensity modulated radiotherapy and volumetric
modulated arc therapy (VMAT), it is possible to deliver
high doses of radiation to irregular target volumes whilst
sparing normal tissue, which can result in reduced seve-
rity of radiation toxicities [1]. Increased dose delivery
and dose conformity has led to a greater significance on
the accurate localization of the gross tumour volume
(GTV) and neighbouring structures.
In radiotherapy (RT) planning, computed tomography
(CT) remains the first choice since it provides accurate
dosimetric information. Imaging modalities such as mag-
netic resonance imaging (MRI) and positron emission
tomography (PET) may present advantages compared to
CT in terms of target definition. In particular, MRI offers
improved soft tissue contrast [2,3] and reduced artefacts
from dental amalgam; hence, MRI is the imaging moda-
lity of choice for oropharyngeal cancers [4]. MRI im-
proves target definition for patients with head and neck
[5-7], prostate [8,9] and brain [10,11] cancer.
Challenges with MRI in clinical practice include: geo-
metric distortion [12,13]; motion related artefacts [14]
and magnetic susceptibility [15,16]. Patient positioning
must also be considered, since differing patient set-ups
between modalities can result in uncertainties in the
location and magnitude of the GTV and thus the dose
received by the patient [17].
Patients receiving RT to the brain can undergo an MRI
in the RT position within an immobilization mask, with-
out loss of image quality over standard imaging methods
[18]. An approximate image registration uncertainty of
2 mm occurs when registering CT image sets in the treat-
ment position to a diagnostic MRI for patients with brain
cancer [19] and therefore many RT centres routinely regis-
ter these scans for RT planning. While it could be antici-
pated that imaging patients with oropharyngeal cancer in
the treatment position would result in improved registra-
tion and target volume definition, to our knowledge there
is no published evidence to suggest that using the diagnos-
tic MRI provides results to the contrary. In addition, no
publications have analyzed the dosimetric consequences
of patient positioning during MRI scan acquisition.
The purpose of this study was to compare an MRI ac-
quired with a diagnostic patient position on a standard
MRI table to an MRI acquired on a flat table with
custom immobilization and to determine how this af-
fects CT-MRI registration, GTV definition, the resulting
VMAT RT plans and the magnitude of the associated
geometric and dosimetric errors. The results obtained
would then provide an answer to whether it was neces-
sary to obtain a planning MRI scan for patients with
oropharyngeal cancer in the RT treatment position using
an immobilization mask or whether a diagnostic patient
position protocol would suffice.Methods
Patient group and study overview
Twenty two patients with oropharyngeal cancer (age
37–72), being worked up for radical RT (patients being
treated with curative intent), were identified for the
study, regardless of tumour or nodal stage. The study
protocol was approved by Local Ethics Committee (West
of Scotland Research Ethics Service, Western Infirmary,
Glasgow G11 6NT, Scotland, UK) and informed written
consent was obtained from all patients. Registration
quality assessment was conducted on all patients, how-
ever, in three patients a GTV evaluation was not pos-
sible, since two patients had undergone primary surgical
resection and another had received induction chemo-
therapy, resulting in complete response.
Patients underwent a CT planning scan, and two MRI
scans (patients scanned between February 2010 and
January 2012; median time between CT and MRI scans =
5 days, range = 0 to 21 days). The first MRI scan was
obtained with the patient in the standard diagnostic pos-
ition (denoted as MRID) and the second with the patient
in an immobilization mask in the RT position (MRIRT).
Both MRI scans were registered separately with the CT
planning scan as shown in Figure 1. The GTV was de-
lineated on the CT images by trained Consultant Radi-
ation Oncologists using the treatment planning system,
with the aid of viewing MRID on a separate console.
This patient position protocol is denoted as PPC. This
is the current standard practice at out centre, and
would be considered standard practice in the majority
of institutions in this country. For the purposes of this
study, the GTV was delineated using two other patient
set-ups. Firstly, the GTV was delineated on the MRID
registered to the CT datasets. This patient position
protocol is denoted as PPD. The GTV was also deli-
neated on the MRIRT registered to the CT image sets,
denoted as PPRT.
CT and MRI scanning protocol
Patients were scanned on a GE Light-speed RT 16 slice
CT scanner (GE Healthcare, WI, USA), using the current
clinical scanning protocol, and immobilized within a full
face and neck five point fixation thermoplastic beam di-
rectional shell (BDS) with appropriate head rest (CIVCO
Medical Solutions, IA, USA). The scan extent was from
superior orbital ridge to carina. A helical scan was ac-
quired with a detector configuration of 16 × 1.25, pitch
0.938, matrix 512 × 512 and speed 18.75 mm/rot with a
slice thickness of 2.5 mm.
Patients underwent MRI scans in two different posi-
tions during the same scan session. For the MRIRT scan,
patients were positioned on a flat MRI Oncology Table
(GE Healthcare, WI, USA), within a BDS, with a 4-
channel flexible surface cardiac coil positioned laterally
(b)
(a)
Figure 1 Split view showing the registration in the axial, coronal and sagittal planes of (a) the CT and MRID and (b) the CT and MRIRT
datasets. Arrows indicate regions where there is a registration mismatch between CT and MRID. Typically, more discrepancies in registration
occurred with MRID than MRIRT. MRID: diagnostic MRI scan; MRIRT: radiotherapy positioned MRI scan.
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as the CT scan was employed and the imaging parame-
ters, chosen in accordance with local protocol, are
presented in Table 1.
The scan was repeated for the MRID on a standard
curved diagnostic table without BDS using a 16-channelFigure 2 MRI acquired in the radiotherapy position with a 4-channelhead, neck and spine coil, with the CT scan extent. The
16-channel head, neck and spine coil was not used for
the MRIRT scan since it is not compatible with the BDS.
A previous investigation using test objects has shown
the image quality obtained using the 4-channel cardiac
coil is of diagnostic quality [18].flexible surface coil positioned laterally.
Table 1 MRI imaging parameters
Scan type FOV* (mm) Slice thick (mm) Spacing (mm) TE† (ms) TR†† (ms) Bandwidth
(± kHz)
Matrix size
2D Driven-equilibrium FSE (T2-weighted) 400 2.5 0 94 2620 63 512 × 256
3D Spoiled gradient echo (T1-weighted
post-contrast)
400 2.5 0 2 15 50 256 × 256
* Field of view.
† Echo time.
†† Repetition time.
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The treatment planning system (Eclipse, Varian Medical
Systems, Inc. CA, USA, version 10.0.39) was used to
register the MRIRT and MRID T1 and T2-weighted scans
to the CT data. This software enabled fully automated,
mutual-information based rigid registration to be per-
formed. While deformable registration is available for
Eclipse, it does not allow inter-modality registration.
Since commercial inter-modality deformable image
registration is generally not available, nor employed clin-
ically in our centre at present, this was not subject to
further investigation. The volume over which the regis-
tration was performed was centred over the oropharyn-
geal region and chosen to include as much information
for the registration algorithm as possible [6]. Fully auto-
mated registration was used without manual adjustment
since, for this site, satisfactory registration for both tar-
get and nodes is not always achievable and would intro-
duce subjective errors.
To quantitatively assess the quality of registration the
orbits and the odontoid process were outlined on the
CT and T1-weighted MR image sets. These three struc-
tures were delineated on the CT, for each patient, and
then repeated on the MR datasets registered to the CT.
Two metrics determined the quality of registration.
Firstly, the distance between the centre of the orbits and
odontoid process drawn on the CT and the MRI datasets
was calculated using the coordinate location of the
centre of the structures determined by the treatment
planning software. The geometric mean was calculated
to ensure normality of the data. Secondly, the quality of
registration was assessed by measuring the spatial
overlap of these structures drawn on CT and MRI. The
spatial overlap was assessed by calculating the Dice coef-
ficient (spatial overlap) for each structure, which is given
by,
spatial overlap ¼ CT∩MRI
CTþMRIð Þ=2
where CT ∩ MRI is the volume of intersection between
the CT and MRI structures. The value of the spatial
overlap can range from zero, which indicates no spatial
overlap between the CT and MRI volumes, to one,
which indicates complete overlap [20]. Since structuresoutlined on CT and MRI may differ, even with perfect
registration, a spatial overlap of one may not be achieved
in practice, but will still be dependent on different pa-
tient set-up and registration quality.
Gross tumour volume, lower risk clinical target volume
and organ at risk delineation
Three Oncologists were assigned five patients each and
a fourth was assigned four patients. The Oncologists de-
lineated the GTV on their patients using the three set-ups
PPC, PPD and PPRT, which in this study are referred to as
GTVC, GTVD and GTVRT respectively. Anonymized in-
formation sheets, containing the patient’s clinical history
and radiology report, were available to the Oncologists.
The clinicians generally utilized the T2-weighted MR
datasets while contouring the GTV, although T1-weighted
images were also referenced. A period of at least a week
was given between delineations of the GTV for the same
patient using a different imaging protocol and the Oncolo-
gists were blinded to previous delineations. Changes in
the magnitude of the GTV were assessed. Contouring was
also performed on the lower risk clinical target volume
(CTV LR) of the nodal areas at risk of microscopic in-
volvement for a randomly selected cohort of ten patients,
in each of the set-ups. Nodal delineation was performed
according to international consensus guidelines [21]. For
these patients, the organs at risk (OARs), which included
the left and right parotids, larynx, spinal cord and the
brainstem, were also contoured.
The GTV and CTV LR were expanded to obtain plan-
ning target volumes, (PTV) and lower risk planning target
volumes (PTV LR) respectively. To create the clinical
target volume (CTV) the GTV was expanded by 1 cm iso-
tropically, removing any overlap with bone or air cavities.
The CTV was then enlarged by 3 mm isotropically and
cropped from the external outline of the body to create
the PTV. It is necessary to crop the PTV from the body
outline to assist in the VMAT optimization process. The
PTVs were generated from the GTVs using the three set-
ups PPC, PPD and PPRT, which are denoted as PTVC,
PTVD and PTVRT respectively. Similarly, to generate the
PTV LR the CTV LR was expanded by 3 mm isotropically
and cropped by an appropriate margin from the body
outline. Target volumes and OARs were generated in
accordance with local protocol.
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VMAT plans were calculated for the ten patients for
whom the GTV, CTV LR and OARs were contoured, to
determine the impact that changes in target volume def-
inition have on RT planning. The VMAT plans were cal-
culated in accordance with our centre’s clinical dose
constraints using the Anisotropic Analytical Algorithm
and Progressive Resolution Optimizer VMAT algorithm
in Eclipse (Varian Medical Systems, Inc, CA, USA) ver-
sion 10.0.28. A VMAT plan was calculated for PTVC,
PTVD and PTVRT. Dose volume histograms (DVHs) were
generated for PTVC, PTVD and PTVRT. A mean DVH for
all ten patients was then calculated for PPC, PPD and
PPRT. These results are presented using our centre’s dose
constraint protocol i.e. D99 > 90%, D95 > 95%, D5 < 105%
and D2 < 107%, where D99 > 90% means 99% of the total
PTV volume should receive a dose > 90% of the prescribed
dose. The other dose constraints are defined similarly.
Of particular interest in this study was to establish the
quality of the RT plan for PPC and PPD with reference to
PPRT, since our working hypothesis postulates that the
optimum target volume definition is achieved with PPRT.
To achieve this we optimized for PTVC and PTVD but
investigated the dose coverage of PTVRT at D99 > 90%,
D95 > 95%, D5 < 105% and D2 < 107%.
A quantitative comparison of the homogeneity of the
dose to the PTV was completed using the sigma index.
The sigma index was compared individually for PTVC,
PTVD and PTVRT as well as for PTVC, PTVD with refe-
rence to PTVRT. The sigma index is equal to the standard
deviation of the dose throughout the PTV, calculated on
a voxel by voxel basis [22], thus the higher the sigma
index, the greater the dose inhomogeneity.Figure 3 Quality of registration results. The geometric mean CT-MRI reg
of the CT structures to the centre of the MRI structures. The error bars repr
CT registered with the diagnostic MRI scan; CT-MRIRT: CT registered with raFinally, the dose to the OARs was assessed by evalua-
ting the mean and maximum dose received using PPC,
PPD and PPRT.
Two-tailed paired student t-tests were performed to
examine the statistical differences of the registration
quality and dosimetric indices, except for the geometric
mean distance from the centre of structures in CT and
MRI where two-tailed Mann–Whitney tests were
performed. A Mann–Whitney test was used to assess
the geometric mean distance from the centre of the
structures because the data was not normally distrib-
uted. The null hypothesis was rejected when the p value
was less than 0.05.
Results
There was a reduction in the geometric mean distance
from the centre of the orbits and odontoid process de-
lineated on the CT and MRIRT to that delineated on the
CT to MRID volumes (Figure 3) and this was significant
(p value < 0.001) for each structure. Narrower error bars
exist for the CT registered to the MRIRT versus the
MRID, which strongly implies that the patients are posi-
tioned more closely to their CT set-up in the BDS than
when using the ordinary diagnostic set-up. No correl-
ation was found between the time from the CT and MRI
scan in days and the mean registration error for either
MRID (R
2 = 0.06) or MRIRT (R
2 = 0.02).
An improvement in the mean spatial overlap for the
orbits and odontoid process was observed between CT
and the CT-MRIRT over the CT to CT-MRID data sets
as shown in Table 2. Analyzing the difference between
the spatial overlap of CT to CT-MRID versus CT to CT-
MRIRT was shown to have a p value < 0.001 for bothistration error is the geometric mean of the distance from the centre
esent ± 1 standard deviation. Odontoid: odontoid process; CT-MRID:
diotherapy positioned MRI scan.
Table 2 Mean spatial overlap of the anatomical






Left orbit 0.49 0.81 < 0.001
Right orbit 0.48 0.81 < 0.001
Odontoid process 0.37 0.67 < 0.001
* CT registered with diagnostic MRI.
† CT registered with the radiotherapy positioned MRI.
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the three structures delineated on CT was larger than
those delineated on MRI, however, their mean difference
was within one standard deviation. Therefore, the spatial
overlap is expected to give a good measure of the quality
of registration.
The mean GTVC was significantly larger than the
GTVD or GTVRT as shown in Table 3. The p values in
Table 3 refer to the differences in the magnitude of the
GTVC and the other two GTVs. There was no signifi-
cant difference between GTVD and GTVRT (p value =
0.14).
Clinical dose constraints were met for the mean DVHs
of PTVC, PTVD and PTVRT (columns 3–5 of Figure 4
(a)), which validates the planning methodology in this
study. When optimizing the RT plan for PTVC, or re-
peating the optimization process for PTVD, the dose to
PTVRT shows that neither the D99 nor the D95 dose con-
straints are met for the mean DVHs of PPC or PPD (the
last 2 columns of Figure 4(a) and (b)). For example, for
D99 mean dose to the PTV for PTVD: PTVRT is 14.9%
rather than the 90% required. Conformity to dose con-
straints is poorer for PTVD: PTVRT compared to PTVC:
PTVRT (Figure 4(b)). Only by using PPRT can all dose
constraints be achieved for PTVRT.
The justification for choosing only ten patients to per-
form the dose analysis was that none of the ten patients
met the 90% dose constraint for PTVC: PTVRT and
PTVD: PTVRT and only one of the ten patients met the
95% dose constraint for both PTVC: PTVRT and PTVD:
PTVRT. This relates to a 95% confidence interval of 0.0%
to 30.9% and 0.3% to 44.5% respectively. These confi-
dence intervals demonstrate that no further cases are
statistically necessary in the analysis.Table 3 Mean GTV* (cm3) delineated with the different
patient position protocols
Mean GTVC† Mean GTVD†† (p value) Mean GTVRT
# (p value)
44.1 33.7 (0.027) 30.5 (0.014)
The p value relates to differences in the magnitude of GTVC and the other
two GTVs.
* Gross tumour volume.
† GTV delineated on CT with diagnostic MRI scan viewed separately.
†† GTV delineated using the CT registered with diagnostic MRI.
# GTV delineated using the CT registered with radiotherapy positioned MRI.Figure 5 demonstrates for a typical patient the PTVRT
and the dose distributions optimized for PTVC (left) and
PTVD (right). This figure shows that the 95% isodose
line does not cover PTVRT entirely with a posterior
proportion of the PTV receiving a dose less than 95% of
the prescribed dose. Figure 5 is in agreement with the
results of Figure 4 which shows that when optimizing
for PTVC or PTVD not all the dose constraints are met
for PTVRT.
The mean sigma indices are shown in Table 4. In the
first three columns of Table 4 the sigma indices are
within 3.3% again validating the planning methodology in
this study. The dose homogeneity becomes considerably
poorer for PTVC: PTVRT and PTVD: PTVRT at 7.3% and
9.1% respectively. A statistically significant difference be-
tween the sigma indices was found between PTVC: PTVC
and PTVC: PTVRT (p value = 0.004) and between PTVD:
PTVD and PTVD: PTVRT (p value = 0.008). The mean
sigma index for PTVD: PTVRT is poorer than for PTVC:
PTVRT in agreement with the results of Figure 4(a).
Results for parotid and larynx OAR dose analyses are
presented in Table 5. In situations where there was over-
lap between a parotid and PTV, it was considered that
dose sparing to that parotid was not possible without
compromising PTV dose; hence it was excluded from
the analysis. The results demonstrate that in planning
PTVC, PTVD and PTVRT, in all 10 patients the mean
dose to the parotid was < 2400 cGy which met clinical
dose constraints. However, when RT plans were opti-
mized for PTVC and PTVD and the dose to the parotid
for PPRT were analysed (PTVC: PTVRT and PTVD: PTVRT)
in 5 out of 10 patients the parotid dose exceeded the toler-
ance. For the larynx, the tolerance of 4000 cGy was
exceeded in 4 out of 10 for PPC, 3 out of 10 for PPD and 1
out of 10 patients for PPRT. However, as with the parotid,
when RT plans were optimized for PTVC and PTVD and
the dose to the larynx for PPRT were analysed there were
more instances of unmet dose constraints (5 out of 10 pa-
tients for both PTVC: PTVRT and PTVD: PTVRT).
When the mean dose to the parotid and larynx for all
10 patients was calculated, an incrementally smaller
value was seen for PTVC, PTVD and PTVRT (first 3 col-
umns of Table 5), which can be explained by the de-
crease in the magnitude of the GTV. Dose to the spinal
cord and brainstem were also calculated but were not
found to exceed clinically relevant tolerances for any of
the patient position protocols.
Discussion
Advanced imaging techniques have been shown to im-
prove tumour and nodal staging [23] and the benefits of
integrating MRI are well known [5-7,23,24]. While the
advantages in positioning patients in a similar way to
their CT planning scan when acquiring MR images are
(a)
(b)
Figure 4 Mean DVH values and mean DVHs. (a) Values obtained from mean DVHs optimizing for each PTV but investigating the dose to each
PTV and (b) mean DVHs optimizing for each PTV but investigating the dose to PTVRT. The PTV left of the colon indicates the PTV for which
the VMAT plan was optimized and right of the colon indicates the PTV under examination. DVH: dose volume histogram; PTVC: PTV delineated
using the CT with the diagnostic MRI scan viewed on a separate console; PTVD: PTV delineated on the CT registered with the diagnostic MRI
scan; PTVRT: PTV delineated on the CT registered with the MRI scan in the radiotherapy position.
Figure 5 PTVRT and the dose distributions optimized for PTVC (left) and optimized for PTVD (right). PTVRT: PTV delineated on the CT
registered with the MRI scan in the radiotherapy position; PTVC: PTV delineated using the CT with the diagnostic MRI scan viewed on a separate
console; PTVD: PTV delineated on the CT registered with the diagnostic MRI scan.
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Table 4 Mean sigma indices for the PTVs
PTVC: PTVC* PTVD PTVD† PTVRT: PTVRT†† PTVC: PTVRT PTVD: PTVRT
Mean sigma index (%) 3.0 3.1 3.3 7.3 9.1
PTV left of the colon indicates the PTV for which the VMAT plan was optimized and right of the colon the PTV under examination.
* PTV delineated using the CT with diagnostic MRI viewed separately.
† PTV delineated on the CT registered with diagnostic MRI.
†† PTV delineated on the CT registered with radiotherapy positioned MRI.
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the CT-MRI registration accuracy and dosimetric effects
of a diagnostic versus RT positioned MRI scan in pa-
tients with oropharyngeal cancer.
During the process of registering CT to MR images,
there was improved registration with fewer discrepancies
using MRIRT compared to MRID, as demonstrated in
Figure 1. In this example, there are registration discrep-
ancies at the body outline and spinal cord for CT-MRID,
as indicated by the arrows (Figure 1(a)), but not with
MRIRT (Figure 1(b)).
A significant improvement in the registration quality
of CT to MRIRT versus the MRID was demonstrated by a
reduction in the geometric mean distance from the
centre of the orbits and odontoid process delineated on
CT and the MRIRT and an increase in the spatial overlap
of these structures. These results show that patient setup
significantly influences CT-MRI registration accuracy.
With increased interest in the use of dose escalation and
dose painting techniques within RT planning the im-
portance of improved image registration becomes ever
more relevant.
The significant difference between the magnitude of
the GTVC and GTVD and between the GTVC and
GTVRT implies that the GTV is significantly smaller
when using registered rather than unregistered CT-MR
images. This underlines the importance of registering












Number of patients which exceed the dose constraint 4
Where there was overlap between a parotid and the PTV the parotid dose was not
position protocol for which the VMAT plan was optimized and right of the colon in
* Patient position protocol: CT and diagnostic MRI scan viewed separately.
† Patient position protocol: CT registered with the diagnostic MRI.
†† Patient position protocol: CT registered with radiotherapy positioned MRI.rather than viewing them separately. It also highlights
the difficulty in delineating oropharyngeal cancers with
CT due to the similarity in Hounsfield Units of tumour
and surrounding tissue as well as artefacts caused by
dental amalgam. While there was no significant differ-
ence between the mean GTVD and GTVRT, there were
important differences in the VMAT plans, as discussed
below. To achieve the clinical goal of reduced late toxic-
ities and improved tumour control using dose escalation
with tighter PTV margins, uncertainties in GTV delinea-
tion need to be minimized and our data suggest PPRT of-
fers the optimal of the three set-ups.
The results reveal that there are potentially clinically
relevant improvements to the quality of the VMAT plans
when using PPRT rather than PPC or PPD. This is dem-
onstrated by the PTV dose coverage, PTV dose homo-
geneity and instances of unmet dose constraints by the
OARs. Due to improved registration accuracy and MRI
being the recommended imaging modality for soft tissue
oropharyngeal cancers [4], it may be assumed that
PTVRT would be the reference PTV. To determine the
dose received by the reference, PTVRT, we optimized for
PTVC and PTVD while calculating the dose to PTVRT.
When optimizing for PTVRT it was shown that the mean
DVH for PTVD had poorer dose coverage than PTVC
(Figure 4). Despite the magnitude of the mean GTVRT
and GTVD being similar there may be differences in the
shape and location of the GTV using these patient set-dose (cGy)
nstraint 2400 cGy
PPD: PPD† PPRT: PPRT†† PPC: PPRT PPD: PPRT
1965.5 1820.3 2233.8 1992.4
0 0 5 5
dose (cGy)
nstraint 4000 cGy
PPD: PPD PPRT: PPRT PPC: PPRT PPD: PPRT
3892.3 3613.2 4108.8 4020.6
3 1 5 5
included in the mean parotid dose. PP left of the colon indicates the patient
dicated the patient position protocol under examination.
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the PPC nor the PPD VMAT plans were able to meet the
clinical dose constraints of D99 and D95 for the reference,
PTVRT. Furthermore, it has been argued that tumour con-
trol probability can be considerably compromised by an
inhomogeneous dose to the PTV [25]. It is therefore sub-
optimal to use PPC or PPD rather than PPRT for RT plan-
ning of patients with oropharyngeal cancer.
Obtaining a further MRI in the RT position, rather than
using the original diagnostic MRI, may place greater de-
mands on increasingly stretched healthcare resources. How-
ever, this must be weighed against the potential advantages
of improved image registration and, by consequence, super-
ior target volume definition and dose coverage of the PTV,
as these results have demonstrated. Our study suggests fur-
ther research, particularly in correlating dosimetric investi-
gations with clinical outcome data, would be warranted.
Conclusions
When MRI scans are performed in the RT position, as op-
posed to using diagnostic MR images not obtained in RT
position, there are significant improvements in the quality
of CT-MR registration. This study has also shown that RT
positioned MRI scans offer improvements in target defin-
ition, dose coverage and dose homogeneity, which could
have significant implications for tumour control rates. To
our knowledge, this is the first study in the literature to
confirm these advantages.
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generated from GTVC; PTVD: Gross tumour volume generated from GTVD;
PTVRT: Gross tumour volume generated from GTVRT; RT: Radiotherapy;
VMAT: Volumetric modulated arc therapy.
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